NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,038,467 | +1906.0% | 1,743,565 | +1837.3% | 0.01% | +1100.0% |
| Q2 2023 | $51,768 | +36.1% | 90,000 | +283.4% | 0.00% | – |
| Q3 2022 | $38,038 | -15.5% | 23,476 | +100.0% | 0.00% | -100.0% |
| Q2 2022 | $45,000 | -18.2% | 11,738 | +14.8% | 0.00% | 0.0% |
| Q1 2022 | $55,000 | -86.9% | 10,227 | -47.3% | 0.00% | -87.5% |
| Q4 2019 | $419,000 | +65.0% | 19,422 | +171.7% | 0.01% | +14.3% |
| Q2 2019 | $254,000 | -8.3% | 7,148 | +57.4% | 0.01% | -30.0% |
| Q3 2018 | $277,000 | -86.6% | 4,541 | -76.7% | 0.01% | -93.5% |
| Q1 2018 | $2,069,000 | – | 19,473 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |